Effects of Extracorporeal Shockwave Therapy on Systemic Sclerosis: A Review Study
Novelty in Biomedicine,
Vol. 13 No. 4 (2025),
28 October 2025
,
Page 228-232
https://doi.org/10.22037/nbm.v13i4.46713
Abstract
Background: Systemic sclerosis (SSC) is an uncommon chronic autoimmune disorder that can involve several organs. The manifestations of SSC occur due to fibrosis in the tissue. Patients with SCC experience stiffness in skin, muscles, and calciumic mass that are known as calcinosis cutis. Extracorporeal shock wave therapy (ESWT) is a safe rehabilitation method that is used in different disorders. The use of ESWT in SSC has not been well-assessed. In this study, we aimed to review the effects of ESWT on systemic sclerosis.
Materials and Methods: We reviewed studies that were published from 2010 to 2023. Five studies were found that evaluated the effects of ESWT on SSC. Fifty-nine patients were assessed in these studies.
Results: The results of studies demonstrated that ESWT reduced pain and skin stiffness. It has remarkable effects on endothelial progenitor cells, endothelial cells, endothelial growth factor, and von Willebrand factor. No side effects were reported in the studies.
Conclusion: This article aims to review the evidence regarding virus-induced anemia, detailing mechanisms such as erythroid progenitor cytotoxicity, chronic inflammation, and treatment-related haemolysis. Diagnostic strategies, ranging from serological assays to pathognomonic bone marrow findings, are discussed to assist laboratory science professionals and clinical specialists in diagnosing, treating, and managing patients with anemia.
- Extracorporeal shockwave therapy
- Systemic scleroderma
- Systemic sclerosis
How to Cite
References
1. D’Silva KM, Bolster MB. Systemic Sclerosis: A Comprehensive Approach to Diagnosis and Management. Physician Assistant Clinics. 2021;6(1):159-75.
2. Politikou O, Giesen T, Reissner L, Calcagni M. Hand and wrist joint procedures in patients with scleroderma: a systematic review. Journal of Hand Surgery (European Volume). 2019;44(4):402-07.
3. Beldner S, Rabinovich RV, Polatsch DB. Scleroderma of the hand: evaluation and treatment. JAAOS-Journal of the American Academy of Orthopaedic Surgeons. 2020;28(16):e686-e95.
4. Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Paper presented at: Seminars in Arthritis and Rheumatism2013.
5. Nowaczyk J, Zawistowski M, Fiedor P. Local, non-systemic, and minimally invasive therapies for calcinosis cutis: a systematic review. Archives of Dermatological Research. 2022;314(6):515-25.
6. Saito S, Ishii T, Ito K, Shimokawa H. Extracorporeal shock wave therapy for digital ulcers associated with systemic sclerosis. Journal of Scleroderma and Related Disorders. 2016;1(2):181-5.
7. Belloli L, Cugno M, D’Agostino M, et al. Shock wave therapy for systemic sclerosis. Rheumatology international. 2013;33:1099-100.
8. Tinazzi E, Amelio E, Marangoni E, et al. Effects of shock wave therapy in the skin of patients with progressive systemic sclerosis: a pilot study. Rheumatology international. 2011;31:651-6.
9. Blumhardt S, Frey DP, Toniolo M, Alkadhi H, Held U, Distler O. Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis. Clin Exp Rheumatol. 2016;34(5):177-80.
10. Sultan-Bichat N, Menard J, Perceau G, Staerman F, Bernard P, Reguiaï Z. Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy. Journal of the American Academy of Dermatology. 2012;66(3):424-9.
11. Sierakowska M, Doroszkiewicz H, Sierakowska J, et al. Factors associated with quality of life in systemic sclerosis: a cross-sectional study. Quality of Life Research. 2019;28:3347-54.
12. Sierakowska M, Sierakowski S, Sierakowska J, Krajewska-Kułak E, Ndosi M. Pain, fatigue and functional disability are associated with higher educational needs in systemic sclerosis: a cross-sectional study. Rheumatology International. 2018;38(8):1471-8.
13. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmunity reviews. 2010;9(5):A311-A8.
14. Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Annals of the rheumatic diseases. 2017;76(8):1327-39.
15. Sierakowska M, Rudzik T. Nursing care for people with rheumatic diseases. Nursing internship. 2017:335-373.
16. Sun M, Jamal S, Kur J. Analysis of Rheumatology Nursing Interventions in Out-patient Practice Settings. J Canadian Rheumatol Assoc (CRAJ)[Internet]. 2014;24(3).
17. Wong CW-Y, Ng EY-L, Fung P-W, Mok K-M, Yung PS-H, Chan K-M. Comparison of treatment effects on lateral epicondylitis between acupuncture and extracorporeal shockwave therapy. Asia-Pacific journal of sports medicine, arthroscopy, rehabilitation and technology. 2017;7:21-6.
18. Crevenna R, Mickel M, Keilani M. Extracorporeal shock wave therapy in the supportive care and rehabilitation of cancer patients. Supportive Care in Cancer. 2019;27:4039-41.
19. Simplicio CL, Purita J, Murrell W, Santos GS, Dos Santos RG, Lana JFSD. Extracorporeal shock wave therapy mechanisms in musculoskeletal regenerative medicine. Journal of Clinical Orthopaedics and Trauma. 2020;11:S309-S18.
20. De la Corte-Rodríguez H, Román-Belmonte JM, Rodríguez-Damiani BA, Vázquez-Sasot A, Rodríguez-Merchán EC. Extracorporeal shock wave therapy for the treatment of musculoskeletal pain: a narrative review. Paper presented at: Healthcare. 2023.
21. Ferrante A, Guggino G, Di Liberto D, et al. Endothelial progenitor cells: Are they displaying a function in autoimmune disorders? Mechanisms of Ageing and Development. 2016;159:44-8.
22. Ota Y, Kuwana M. Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. European Journal of Rheumatology. 2019;7(Suppl 3):S139.
23. Mostmans Y, Cutolo M, Giddelo C, et al. The role of endothelial cells in the vasculopathy of systemic sclerosis: a systematic review. Autoimmunity reviews. 2017;16(8):774-86.
24. Scheja A, Åkesson A, Geborek P, et al. Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma). Arthritis Research & Therapy. 2001;3:1-6.
25. Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. Journal of scleroderma and related disorders. 2017;2(1):11-8.
26. Devlin NJ, Brooks R. EQ-5D and the EuroQol group: past, present and future. Applied health economics and health policy. 2017;15:127-37.
- Abstract Viewed: 86 times
- pdf Downloaded: 69 times